Aflac AFL Cancer — Interest accrual
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aflac in its filing.
Tagged under the XBRL concept us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpense.
The official record: Aflac’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aflac's cancer — interest accrual.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aflac's cancer — interest accrual?
- Aflac (AFL) reported cancer — interest accrual of $303M in Q1 2026.
- How has Aflac's cancer — interest accrual changed year-over-year?
- Aflac's cancer — interest accrual decreased by 6.5% year-over-year, from $324M to $303M.
- What is the long-term trend for Aflac's cancer — interest accrual?
- Over 4 years (2021 to 2025), Aflac's cancer — interest accrual has grown at a -10.4% compound annual growth rate (CAGR), from $2.01B to $1.3B.
- What does cancer — interest accrual mean?
- Represents the accretion of interest on the liability for future policy benefits within the cancer insurance segment. This reflects the time value of money applied to long-duration insurance contracts as the company moves closer to the expected payout date.